M&G plc’s Acadia Pharmaceuticals ACAD Stock Holding History

M&G plc’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-351,115	Closed	-$5.62M	–	409
2024 Q2	$5.62M	Buy	351,115 +38,790	+12%	+$626K	0.02%	260
2024 Q1	$5.62M	Buy	+312,325	New	+$7.74M	0.02%	286

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

M&G plc's ACAD Position: Q3 2024 in Review

M&G plc sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 351,115 shares — an estimated $5.62M sold.

M&G plc first reported a position in ACAD in Q1 2024 and held it in 2 quarters. The position peaked at $5.62M in Q1 2024. 256 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

M&G plc reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
M&G plc sold 351,115 Acadia Pharmaceuticals shares in Q3 2024, an estimated $5.62M.
M&G plc first reported a position in Acadia Pharmaceuticals in Q1 2024 and held it in 2 quarters.
M&G plc's Acadia Pharmaceuticals position peaked at $5.62M in Q1 2024.
256 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on M&G plc's 13F filing for Q3 2024, filed 31 Oct 2024.